Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
Justyna Kocik1, Monika Machula1, Aneta Wisniewska1
1Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, ul. Gronostajowa 2, 30-387 Krakow, Poland.
Abstract:
The protein p53, known as the "Guardian of the Genome", plays an important role in maintaining DNA integrity, providing protection against cancer-promoting mutations. Dysfunction of p53 is observed in almost every cancer, with 50% of cases bearing loss-of-function mutations/deletions in the TP53 gene. In the remaining 50% of cases the overexpression of HDM2 (mouse double minute 2, human homolog) protein, which is a natural inhibitor of p53, is the most common way of keeping p53 inactive. Disruption of HDM2-p53 interaction with the use of HDM2 antagonists leads to the release of p53 and expression of its target genes, engaged in the induction of cell cycle arrest, DNA repair, senescence, and apoptosis. The induction of apoptosis, however, is restricted to only a handful of p53wt cells, and, generally, cancer cells treated with HDM2 antagonists are not efficiently eliminated. For this reason, HDM2 antagonists were tested in combinations with multiple other therapeutics in a search for synergy that would enhance the cancer eradication. This manuscript aims at reviewing the recent progress in developing strategies of combined cancer treatment with the use of HDM2 antagonists.
Insights
HDM2 antagonists can reactivate the tumor suppressor p53. Combining HDM2 antagonists with other therapies may improve cancer eradication by enhancing p53
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The tumor suppressor protein p53 is crucial for DNA integrity and cancer prevention.
- TP53 gene mutations or HDM2 (human homolog of mouse double minute 2) overexpression inactivate p53 in most cancers.
- HDM2 inhibits p53 activity, and its antagonists can restore p53 function.
Purpose of the Study:
- To review strategies for combined cancer treatment using HDM2 antagonists.
- To explore synergistic effects of HDM2 antagonists with other therapeutics for enhanced cancer eradication.
Main Methods:
- Review of recent scientific literature on HDM2 antagonists and combination therapies.
- Analysis of mechanisms by which HDM2 antagonists affect p53 pathway.
- Evaluation of preclinical and clinical studies investigating combination treatments.
Main Results:
- HDM2 antagonists disrupt the HDM2-p53 interaction, releasing p53 to induce cell cycle arrest, DNA repair, senescence, and apoptosis.
- HDM2 antagonists alone show limited efficacy in eliminating cancer cells.
- Combination therapies involving HDM2 antagonists show potential for synergistic effects.
Conclusions:
- Combined modality treatments involving HDM2 antagonists are a promising strategy for improving cancer therapy outcomes.
- Further research is needed to optimize combination regimens for maximum therapeutic benefit.
- HDM2 antagonists represent a valuable tool in the development of novel cancer treatments.
Related Concept Videos
01:28Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:21Drugs Affecting Neurotransmitter Release or Uptake
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship